- BioNTech halted a mid-stage trial of its mRNA cancer vaccine autogene cevumeran for high‑risk stage II/III colorectal cancer patients after surgery.
- An independent data safety monitoring board spotted a numerical imbalance in overall survival between treatment arms and judged further continuation unlikely to change the result.
- The move, made with partner Genentech (Roche), sent BioNTech’s U.S.-listed shares down nearly 9%.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.